Clinical Trials Browser

Interventional × Depsipeptides × Dermatologic × Clear all

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT02512497 2025-09-19

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Phase 1 Completed

23 enrolled

DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Phase 1 Terminated

17 enrolled

BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT01638533 2025-02-07

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

Phase 1 Completed

37 enrolled

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckLymphoidNETOther hematologic neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Glioma, Lung Neoplasms, Lymphoma, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Thyroid Neoplasms, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Neuroendocrine Tumors, Hematologic Neoplasms

NCT04774068 2025-01-17

Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

Phase 1 Completed

5 enrolled

DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT00104884 2023-06-28

FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Phase 2 Terminated

4 enrolled 4 charts

Dermatologic

Melanoma

NCT00106431 2019-10-30

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

Phase 2 Completed

102 enrolled 15 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

Clinical Trials

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)